Key result
Transitioning from DAPT to single antiplatelet therapy with ticagrelor presents an ongoing clinical dilemma.
Key points are not available for this paper at this time.
Uncertainty in DAPT discontinuation warrants clinical caution; leaves open optimal ticagrelor transition strategies pending higher-level evidence.
SAP, single antiplatelet therapy; TICA, ticagrelor. *The authors’ suggestion.
No takes yet. Share an insight, caveat, or question.
Motovska et al. (2021) studied this question. Discontinuing dual antiplatelet therapy poses a complex clinical dilemma regarding the optimal transition to single antiplatelet therapy such as ticagrelor.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: